18 Nov Has Major Cancer Gene Met It’s Match?

November 18th, 2017 When working on targeted therapeutic drug development in oncology, tumor mutation heterogeneity makes it difficult to treat all patients. However, there is one biomarker that has been found to affect 30% of all tumor cases- the RAS mutation. The abundance of this genomic...

Read More